Gastrointestinal PGx.
Information for GI medication choices. A gene panel for the medications used to treat acid reflux, nausea, vomiting and GI motility — including every common proton pump inhibitor. One saliva sample, run in our CLIA-certified lab, with results your prescriber can refer back to.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
3 genes · CYP2C19, CYP2C9, CYP2D6
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $289
What we test
Panel medications.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Proton pump inhibitors — CYP2C19
Omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole. Rapid CYP2C19 metabolizers clear PPIs so quickly that standard doses may barely lower acid.
Anti-nausea and motility — CYP2D6
Ondansetron, tropisetron, meclizine and metoclopramide — metabolism changes both effect and the risk of side effects such as movement symptoms.
Dronabinol — CYP2C9
Levels of this anti-nausea therapy vary with CYP2C9 metabolism.
Who this is for
Symptoms not well controlled, or side effects at standard doses, often have a metabolism explanation.
Reflux that persists on a PPI
Rapid metabolizers are the classic reason a standard proton pump inhibitor underperforms.
Anti-nausea medication that has not worked
CYP2D6 status changes how well these medications land.
Long-term PPI use
After months on a PPI, genotype can explain whether the dose is really doing anything.
Is this test right for you?
Reflux or heartburn continues on a proton pump inhibitor.
Anti-nausea medication has not worked for you.
You had side effects from metoclopramide or a similar drug.
You have taken a PPI for many months.
You are starting treatment for H. pylori or a GI condition.
Your gastroenterologist suggested genetic testing.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $289
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Who reviews the results
A board-certified geneticist
Every report is reviewed and signed in our lab by a board-certified molecular geneticist before it is released.
The science
What the evidence says about getting tested.
Proton pump inhibitors are among the most prescribed drug classes in the world, and their success depends heavily on one gene: CYP2C19. Rapid metabolizers clear PPIs so quickly that the acid pumps barely switch off; poor metabolizers accumulate far more drug. Nausea and motility medications behave similarly through CYP2D6. CPIC guidelines already recommend genotype-guided PPI dosing — the science is settled enough to act on.
Up to 1 in 4
people carry CYP2C19 rapid-metabolism variants in European populations — standard PPI doses may barely lower acid.
Source: CPIC CYP2C19/PPI guideline
Up to 1 in 5
of people of East Asian ancestry are CYP2C19 poor metabolizers, accumulating far higher PPI levels on standard doses.
Source: CPIC CYP2C19/PPI guideline
Up to 30%
of people on long-term metoclopramide develop movement symptoms — poor CYP2D6 metabolism raises exposure further.
Source: FDA metoclopramide labeling
≈7%
of people are CYP2D6 poor metabolizers, which can change how well anti-nausea medications work.
Source: CYP2D6 pharmacogenetics literature
How often should you test?
Test once — your genotype doesn't change. The highest-value moments are when reflux persists on a proton pump inhibitor, before H. pylori eradication therapy (which depends on PPI levels), before long-term metoclopramide, and whenever anti-nausea medication has underperformed.
References
- CPIC — Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and proton pump inhibitor dosing.
- U.S. National Library of Medicine, DailyMed — metoclopramide prescribing information: movement-symptom warnings with long-term use.
- PubMed literature — CYP2D6 metabolizer status and response to antiemetic medications such as ondansetron.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Questions people actually ask
Bring data to your next GI appointment.
One sample, one flat price, a report your prescribers can refer back to.